How is beta‑thalassemia diagnosed during prenatal screening?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Prenatal Diagnosis of Beta-Thalassemia

Beta-thalassemia is diagnosed during prenatal screening through a sequential approach: first identify at-risk couples via maternal screening (hemoglobin electrophoresis/HPLC showing elevated HbA2 >3.5%), then test the partner, and if both are carriers, proceed with invasive prenatal diagnosis using chorionic villus sampling (CVS) at 10-12 weeks or amniocentesis at 15-18 weeks, followed by DNA mutation analysis.

Screening Algorithm

Step 1: Identify Maternal Carrier Status

  • Screen all pregnant women with complete blood count looking for microcytic hypochromic anemia (MCV <80 fL, MCH <27 pg)
  • Apply discriminant indices to differentiate from iron deficiency:
    • Mentzer index (MCV/RBC): <13 suggests thalassemia trait
    • RDW index and MCH show excellent diagnostic performance 1
  • Confirm with serum ferritin: >15 ng/mL in 95% of beta-thalassemia cases vs <15 ng/mL in iron deficiency 1
  • Perform hemoglobin electrophoresis or HPLC: HbA2 >3.5% confirms beta-thalassemia trait 2, 3

Step 2: Partner Testing

Once maternal carrier status is confirmed, mandatory partner testing is required to determine fetal risk 4. The couple is at-risk only if both partners carry beta-thalassemia mutations or hemoglobin variants (25% risk of affected fetus per pregnancy).

Step 3: Prenatal Diagnosis for At-Risk Couples

Invasive procedures remain the gold standard 5, 6, 7, 8:

Timing and Method:

  • First trimester (preferred): Chorionic villus sampling at 10-12 weeks gestation 5, 8
  • Second trimester: Amniocentesis at 15-18 weeks or cordocentesis 5, 6

Laboratory Analysis:

  • DNA mutation analysis via:
    • Reverse dot-blot hybridization for common mutations (detects 99.4% of cases) 7
    • Direct DNA sequencing for rare mutations 7
    • Multiplex PCR with high-resolution melting analysis 9
  • Common mutations in various populations include IVS-I-110 (G>A), IVS-II-1 (G>A), IVS-I-6 (T>C), CD 41/42-TCTT 5, 7

Expected Results Distribution:

  • 25% affected (homozygous or compound heterozygous)
  • 50% carriers (heterozygous)
  • 25% normal 5, 7, 8

Emerging Non-Invasive Options

Non-invasive prenatal testing (NIPT) using digital PCR on maternal cell-free DNA is becoming available but not yet routine 10, 9:

  • Analyzes cell-free fetal DNA from maternal plasma
  • First screens for paternally inherited mutation (PIB)
  • If PIB-positive, analyzes for maternally inherited mutation (MIB) using mutant/normal allele ratio
  • Cut-off ≥0.919 for MIB detection: 100% sensitivity, 81.2% specificity 9
  • For couples with identical mutations, cut-off ≥1.043: 100% sensitivity and specificity 9
  • Currently limited by cost, availability, and need for validation in routine practice 10, 9

Critical Counseling Components

Genetic counseling must be provided before and after testing 4, 2, 3:

Essential Information to Convey:

  • Nature of carrier state vs disease
  • 25% recurrence risk with each pregnancy when both partners are carriers
  • Clinical manifestations of transfusion-dependent thalassemia
  • Available prenatal diagnostic options and timing
  • Pregnancy termination as an option if fetus is affected
  • Alternative: Preimplantation genetic diagnosis (PGD) for future pregnancies 6, 2

Counseling Effectiveness Factors:

Studies show better knowledge retention with 4:

  • Younger maternal age
  • Higher education level
  • Prior awareness of carrier status
  • Knowledge that partner is also a carrier
  • No prior children

Videotape presentations are as effective as in-person counseling for conveying factual information and save professional time 4.

Important Caveats

  • Cytogenetic analysis should be performed on excess fetal material from CVS/amniocentesis, as 2.3% of cases reveal chromosomal abnormalities 5
  • Partner testing is required for each different partner in subsequent pregnancies—this point requires emphasis as patients often forget 4
  • In regions with high prevalence, universal antenatal screening is recommended rather than selective screening 2, 3
  • Severe anemia in beta-thalassemia trait carriers during pregnancy (hemoglobin <8 g/dL in 33%) increases risk of preeclampsia, postpartum hemorrhage, preterm birth, and IUGR 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.